Goldman Sachs Group Inc vs Intuitive Surgical, Inc. — how do they compare? Goldman Sachs Group Inc trades at $1,037.53 (market cap $301.19B), while Intuitive Surgical, Inc. trades at $402.7 (market cap $141.75B). The key difference: Goldman Sachs Group Inc is far larger — about 2.1× Intuitive Surgical, Inc.'s market cap, and Goldman Sachs Group Inc pays a 1.93% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| GS | ISRG | |
|---|---|---|
Market Cap | $301.19B | $141.75B |
Volume | 2,592,735 | — |
Sector | Financials | Health |
52-Week High | $1.15K | $592.85 |
52-Week Low | $715.95 | $332.02 |
Dividend Yield | 1.93% | — |
Enterprise Value | — | $136.53B |
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,034.51, down 0.49% on the day, with a neutral technical signal and strong fundamental performance. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $20.98 surpassing the $14.47 estimate. Revenue growth is robust, rising to $58.28 billion in 2025, and net income margin expanded to 31.68%. The company is positioned to benefit from a surge in investment banking activity, including leading high-profile IPOs like Anthropic.
The outlook is positive given earnings momentum and strategic positioning in key deals, but risks include volatile cash flows and high leverage. Analyst consensus is a Buy with a $1,160 price target, implying potential upside. Investors should weigh strong profitability against macroeconomic sensitivity and balance sheet pressures.
Intuitive Surgical (ISRG) trades at $403.95, up 2.69% on the day, reflecting strong momentum. The stock exhibits bullish technical signals with support at $398 and resistance at $403. Fundamentally, revenue grew to $10.06B in 2025 with a net income margin of 28.45%, though valuation ratios like a P/E of 46.01 suggest premium pricing. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.80 exceeding expectations. News highlights analyst upgrades and robust adoption of the da Vinci 5 system.
Outlook remains positive driven by innovation and market expansion, but high valuation and competitive pressures pose risks. The consensus price target of $518.10 implies significant upside, supported by 68% buy ratings from analysts. Key risks include reliance on U.S. procedure growth and rising competition from Medtronic and Johnson & Johnson. Long-term growth prospects appear solid if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →